Huntsman Cancer Institute at the University of Utah is the first to be designated as a Clinical and Research Center of Excellence by Pheo Para Alliance. The Alliance dedicates itself to helping ...
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The authors of the finding, from the CNIO, wanted to find out why a specific mutation caused rare tumor pheochromocytoma- paraganglioma in five patients. Succinylation is one of the last steps in the ...
BERLIN -- Belzutifan (Welireg) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm phase II trial, evidence that supported FDA's recent approval in these ...
Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback